
Metformin (1000mg) + Teneligliptin (20mg)
Active composition
+1 more active ingredient
Metformin reduces hepatic glucose production and enhances peripheral insulin sensitivity, lowering blood glucose levels.
Teneligliptin inhibits DPP-4, increasing incretin levels and enhancing insulin secretion.
Medical applications
Ibgliptin-M 1000 Tablet SR is a combination oral antidiabetic medication containing Metformin 1000 mg and Teneligliptin 20 mg, designed for the management of type 2 diabetes mellitus. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake, thereby aiding in glycemic control. Teneligliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances the incretin system by preventing the degradation of incretin hormones such as GLP-1 and GIP, which increases insulin secretion and decreases glucagon release in a glucose-dependent manner. The sustained-release formulation of Ibgliptin-M 1000 ensures prolonged therapeutic plasma concentrations, promoting better compliance and stable glycemic control throughout the day. This combination therapy is indicated for patients inadequately controlled on diet and exercise alone or those requiring dual therapy to achieve target blood glucose levels. It is essential to monitor renal function periodically, as Metformin is contraindicated in patients with significant renal impairment. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, while Teneligliptin is generally well tolerated with a low risk of hypoglycemia when used as prescribed. Ibgliptin-M 1000 Tablet SR should be used under medical supervision with appropriate lifestyle modifications for optimal diabetes management.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
Ibgliptin-M 1000 Tablet SR may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
Medical Advice
Ibgliptin-M 1000 Tablet SR should be used with caution in patients with kidney disease. Dose adjustment of Ibgliptin-M 1000 Tablet SR may be needed. Please consult your doctor. Use of Ibgliptin-M 1000 Tablet SR is, however, not recommended in patients with severe kidney disease. Regular monitoring of kidney function test is advisable while you are taking this medicine.
Exercise Caution
It is not known whether Ibgliptin-M 1000 Tablet SR alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react.
Consult Doctor
Ibgliptin-M 1000 Tablet SR is probably unsafe to use in patients with liver disease and should be avoided. Please consult your doctor.
Regular Checkup
0 reviews for Ibgliptin-M 1000 Tablet SR

Metformin (1000mg) + Teneligliptin (20mg)
Cheaper alternative availability
This medicine doesn't have a cheaper alternative with the same composition. Our health advisors can help you find other savings options based on your prescription.
Active composition
+1 more active ingredient
Metformin reduces hepatic glucose production and enhances peripheral insulin sensitivity, lowering blood glucose levels.
Teneligliptin inhibits DPP-4, increasing incretin levels and enhancing insulin secretion.
Medical applications
Ibgliptin-M 1000 Tablet SR is a combination oral antidiabetic medication containing Metformin 1000 mg and Teneligliptin 20 mg, designed for the management of type 2 diabetes mellitus. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake, thereby aiding in glycemic control. Teneligliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances the incretin system by preventing the degradation of incretin hormones such as GLP-1 and GIP, which increases insulin secretion and decreases glucagon release in a glucose-dependent manner. The sustained-release formulation of Ibgliptin-M 1000 ensures prolonged therapeutic plasma concentrations, promoting better compliance and stable glycemic control throughout the day. This combination therapy is indicated for patients inadequately controlled on diet and exercise alone or those requiring dual therapy to achieve target blood glucose levels. It is essential to monitor renal function periodically, as Metformin is contraindicated in patients with significant renal impairment. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, while Teneligliptin is generally well tolerated with a low risk of hypoglycemia when used as prescribed. Ibgliptin-M 1000 Tablet SR should be used under medical supervision with appropriate lifestyle modifications for optimal diabetes management.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
Ibgliptin-M 1000 Tablet SR may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
Medical Advice
Ibgliptin-M 1000 Tablet SR should be used with caution in patients with kidney disease. Dose adjustment of Ibgliptin-M 1000 Tablet SR may be needed. Please consult your doctor. Use of Ibgliptin-M 1000 Tablet SR is, however, not recommended in patients with severe kidney disease. Regular monitoring of kidney function test is advisable while you are taking this medicine.
Exercise Caution
It is not known whether Ibgliptin-M 1000 Tablet SR alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react.
Consult Doctor
Ibgliptin-M 1000 Tablet SR is probably unsafe to use in patients with liver disease and should be avoided. Please consult your doctor.
Regular Checkup
0 reviews for Ibgliptin-M 1000 Tablet SR













